Recent Settlements Underline the Antikickback Statute's Central Role in Health Care Enforcement

by Baker Donelson
Contact

In recent years, the antikickback statute (AKS) has emerged as an essential legal weapon to combat alleged misconduct in the health care industry. The government’s enforcement patterns reflect how the AKS is increasingly used in tandem with the False Claims Act (FCA) to generate eye-popping civil settlements. In addition, large health care corporations—particularly those in the pharmaceutical sector—face increasing liability exposure for engaging in certain business and marketing arrangements that could be perceived as involving unlawful inducements and referrals. These patterns should inform in-house as well as defense counsel in their efforts to prevent and resolve alleged kickback issues that inevitably arise in the health care setting.

The AKS prohibits the payment or receipt of remuneration in exchange for referrals or the purchase of any item or service that may be covered under a federal health care program. Enacted in 1972, the law prohibits the practice of extending “kickbacks” or provider inducements, which generate conflicted medical decision-making and the provision of unnecessary services that inflate health care costs. Due to the expansive construction of the statute’s prohibition of “remuneration,” the government may use the AKS to challenge a host of business and marketing activities. Given the statute’s broad reach, providers and suppliers are vulnerable to harsh penalties unless their conduct satisfies one of the statutory exceptions or regulatory “safe harbors.”

Although the AKS is a criminal law, statutory violations may also serve as a basis for exclusion from federal health care programs, significant civil money penalties, and damages of up to three times the amount of remuneration at issue. Moreover, with the passage of the Affordable Care Act, it is now well-established that a violation of the AKS qualifies as a “false or fraudulent claim” under the FCA. Now that AKS violations may serve as a predicate offense in an FCA action, the government can target a vast array of transactions and activities, including those located in the remote recesses of the health care world.

Several recent prosecutions reflect how the government is using the AKS and the FCA in a muscular manner to impose massive liability upon health care corporations. In November 2013, Johnson & Johnson and two of its subsidiaries entered into a $2.2 billion settlement to resolve criminal and civil liability arising from allegations involving the off-label promotion of drugs and the payment of kickbacks to physicians and pharmacies to promote prescription sales. As one of the largest health care fraud settlements in history, J&J is required to pay $485 million in criminal fines and forfeiture as well as $1.72 billion in civil damages and penalties under the FCA. Also in 2013, Amgen, Inc. entered into a $24.9 million agreement to settle FCA claims based on allegations that the company paid kickbacks to long-term care pharmacy providers to influence their drug prescribing decisions. Specifically, the company was alleged to have paid performance-based rebates to pharmacies that steered Medicare and Medicaid beneficiaries from using a competitor drug to Amgen’s Aranesp. More recently, Davita HealthCare Partners announced that it will pay $389 million to resolve criminal and civil AKS investigations involving joint venture arrangements with kidney doctors that involved the operation of dialysis centers. The government has maintained that Davita’s joint ventures did not comply with the AKS because the company failed to charge doctors fair-market value in return for the doctors’ ownership stake in certain dialysis centers.

Given the AKS’s compatibility with the FCA and the threat of exclusion from participation in federal health care programs, the government wields extraordinary leverage over corporate defendants. The government is now able to use civil liability—with its lesser standard of proof—to exact far-reaching settlements that have historically been achieved through criminal prosecutions. Additionally, the settlements reveal how the government may use the AKS to target a wide variety of alleged misfeasance and malfeasance in the health care setting, even where the conduct may not resemble “fraud.” This is particularly significant for the pharmaceutical sector, where companies have often used aggressive marketing practices that involve inducements.

While the government’s embrace of the AKS has succeeded in punishing many bad apples, it has also inflated the general cost of doing business in the health care industry. To reduce their vulnerability to government probes and qui tam lawsuits, companies must double-check their business arrangements while doubling-down on their compliance efforts. While these enormous compliance costs may be borne by companies and institutions with sufficient economies of scale, such costs may prove overly burdensome for smaller providers. Moreover, overly aggressive use of the AKS could hamper efforts to engage in the sorts of innovative transactions needed to facilitate the integration of health care delivery—a central desire for industry reform. Nonetheless, regardless of its impact upon health care development and reform, the lure of headlines-grabbing settlements will likely reinforce the government’s embrace of the AKS as one of its primary enforcement tools.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Baker Donelson | Attorney Advertising

Written by:

Baker Donelson
Contact
more
less

Baker Donelson on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.